We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Assertio (ASRT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Assertio is a member of our Medical group, which includes 1187 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Assertio is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for ASRT's full-year earnings has moved 27.3% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ASRT has gained about 8.3% so far this year. At the same time, Medical stocks have lost an average of 20.6%. This means that Assertio is outperforming the sector as a whole this year.
Pliant Therapeutics, Inc. (PLRX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 77.6%.
The consensus estimate for Pliant Therapeutics, Inc.'s current year EPS has increased 6.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Assertio belongs to the Medical - Drugs industry, which includes 217 individual stocks and currently sits at #80 in the Zacks Industry Rank. On average, stocks in this group have lost 30.2% this year, meaning that ASRT is performing better in terms of year-to-date returns.
Pliant Therapeutics, Inc. however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 562-stock industry is ranked #51. The industry has moved -24.5% so far this year.
Investors with an interest in Medical stocks should continue to track Assertio and Pliant Therapeutics, Inc. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Assertio (ASRT - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Assertio is a member of our Medical group, which includes 1187 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Assertio is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for ASRT's full-year earnings has moved 27.3% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ASRT has gained about 8.3% so far this year. At the same time, Medical stocks have lost an average of 20.6%. This means that Assertio is outperforming the sector as a whole this year.
Pliant Therapeutics, Inc. (PLRX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 77.6%.
The consensus estimate for Pliant Therapeutics, Inc.'s current year EPS has increased 6.1% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Assertio belongs to the Medical - Drugs industry, which includes 217 individual stocks and currently sits at #80 in the Zacks Industry Rank. On average, stocks in this group have lost 30.2% this year, meaning that ASRT is performing better in terms of year-to-date returns.
Pliant Therapeutics, Inc. however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 562-stock industry is ranked #51. The industry has moved -24.5% so far this year.
Investors with an interest in Medical stocks should continue to track Assertio and Pliant Therapeutics, Inc. These stocks will be looking to continue their solid performance.